In vivo analysis showed that the cooperative cAGS-STING nanoagonist caused almost complete remission of primary tumors, efficiently suppressed the growth of secondary distal tumors and substantially reduced tumor metastasis without eliciting systemic toxicity, which offers an approach for overcoming the immunoresistance of solid tumor indications. Here, ANKRD17 is linked to neoplasm.